Report Highlights

Cultivated Meat in the U.S.: Market Overview

The U.S. cultivated meat market was valued at USD 0.12 billion in 2024 and is forecast to reach USD 1.11 billion by 2032, a 32% CAGR. Commercial volume remains narrow, concentrated in restaurant pilots and limited retail listings, with hybrid products that blend cultivated cells into conventional or plant-based mince carrying most sales. Market structure is defined by federal jurisdiction under the Federal Food, Drug, and Cosmetic Act and the Federal Meat Inspection Act, which divides premarket review between two agencies.

Government has been the dominant force in shaping the market's current form. FDA completed pre-market consultation for Upside Foods' cultivated chicken in November 2022 and for GOOD Meat's cultivated chicken in March 2023, and USDA FSIS followed with grants of inspection and label approvals in June 2023. Private capital has led on cell line development, bioreactor engineering and product formulation, with Upside Foods, Eat Just and Wildtype raising venture funding to commercialize products that regulators then clear for sale.

Policy-Driven Growth in U.S. Cultivated Meat

Three mechanisms are driving demand. First, the 2019 FDA-USDA formal agreement assigns FDA premarket consultation over cell collection, banking and growth, while USDA FSIS governs production, inspection and labeling of cell-cultured meat and poultry under the Federal Meat Inspection Act and the Poultry Products Inspection Act. Each completed consultation converts a laboratory process into a lawful retail product, which is the mechanism that unlocks restaurant and grocery listings.

Second, Executive Order 14081, signed September 12, 2022, directed federal agencies to advance biomanufacturing, and the USDA National Institute of Food and Agriculture administers the Agriculture and Food Research Initiative, which funds cell culture science for food production. Public research grants lower media and cell line costs, the largest unit-cost component in bioreactor production. Third, FSIS's labeling rulemaking, opened by an advance notice published in September 2021, will set mandatory product naming standards that reduce retailer risk and support shelf placement.

Regulatory Barriers and Compliance Costs

State prohibitions represent the sharpest barrier. Florida enacted SB 1084 in 2024, effective July 1, 2024, banning the manufacture and sale of cultivated meat, and Alabama, Mississippi, Montana, Nebraska, Indiana and Texas have since enacted bans or moratoria, with Texas's two-year ban under SB 261 effective September 1, 2025. State departments of agriculture enforce these measures, so federal approval does not secure access in those seven states.

Federal premarket review adds time and capital. Developers must complete FDA's pre-market consultation before FSIS will grant inspection, and each production site requires a federally inspected facility, a process that the first approved producers spent more than a year completing. Wastewater from cell culture facilities falls under National Pollutant Discharge Elimination System permits issued by the EPA or delegated states under the Clean Water Act, adding permitting costs and monitoring obligations for each plant.

Policy-Created Opportunities in the U.S.

Cultivated fat is the most immediately commercial category. FDA completed its pre-market consultation for Mission Barns' cultivated pork fat in 2025, a product regulated by FSIS as a pork product that can be blended into conventional sausage and plant-based formulations. Ingredient demand avoids the whole-cut tissue scaffolding challenge that slows cultivated chicken and beef, and it sits within the consultation pathway already proven by Upside Foods and GOOD Meat.

Federal research and defense funding create further openings. USDA NIFA's Agriculture and Food Research Initiative and the biomanufacturing priorities under Executive Order 14081 direct grants toward media optimization, scaffolding and serum-free growth systems. The Department of Defense's Distributed Bioindustrial Manufacturing Program also funds regional biomanufacturing capacity, giving cell-culture producers with fermentation or dual-use facilities a route to non-dilutive capital.

Market at a Glance

Leading Market Participants

• Upside Foods
• Eat Just (GOOD Meat)
• Wildtype
• Mission Barns
• BlueNalu
• Fork & Goode
• Believer Meats
• Clever Carnivore
• Mosa Meat
• Meatable

Regulatory and Policy Environment

The primary legislation governing cultivated meat is the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.) and the Federal Meat Inspection Act (21 U.S.C. 601 et seq.), supplemented by the Poultry Products Inspection Act. FDA administers pre-market consultation for cell collection, banking and growth, requiring cell line characterization and safety data, while USDA FSIS administers grants of inspection, facility sanitation requirements and label approval. The 2019 FDA-USDA formal agreement, grounded in the 1986 Coordinated Framework for the Regulation of Biotechnology, divides these responsibilities.

Upcoming changes include FSIS's labeling rulemaking, which remains unfinalized, and the FDA Food Traceability Rule under FSMA Section 204, whose compliance date was extended to July 20, 2028. Texas's two-year moratorium and Indiana's two-year moratorium both expire in 2027. Compared with regional peers, the Singapore Food Agency approved Eat Just's cultivated chicken in December 2020, Israel's Ministry of Health approved Aleph Farms' cultivated beef in January 2024, and the UK Food Standards Agency launched a regulatory sandbox in 2025. The U.S. offers the largest consumer market but the most fragmented state-level rules.

Long-Term Policy Outlook for U.S. Cultivated Meat

By 2032, the most consequential change will be the finalization of FSIS labeling rules, which will define mandatory naming standards for cell-cultured products across retail and foodservice channels. Federal approvals under the Federal Food, Drug, and Cosmetic Act and the Federal Meat Inspection Act will continue to conflict with state prohibitions on sale, and that conflict will be resolved either through federal preemption litigation or through state legislative reversal as moratoria reach their 2027 expiry dates.

Market reshaping will concentrate in cultivated fat, seafood following FDA's 2025 consultation for Wildtype's cultivated coho salmon, and hybrid products. Producers that secure FSIS grants of inspection and multi-state distribution agreements before the 2027 moratorium expiries will lead the market through 2032, while producers relying on single-state sales will face the greatest exposure to policy reversal.